Sermorelin is one of a handful of growth hormone releasing hormone (GHRH) analogues that have been developed in recent years in an effort to preserve some of the positive effects of natural GHRH while avoiding undesirable effects. Sermorelin (Geref) is currently used clinically to assess growth hormone secretion, but the peptide is of additional interest for its abilities to:
- reduce scarring following heart attack,
- increase bone density,
- improve nutrition in chronic illness,
- improve renal function,
- fight the effects of dementia, and
- reduce seizure activity.
